{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:58Z","timestamp":1790701678249,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca R&D Gothenburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.lungcan.2026.109338","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:51:33Z","timestamp":1771433493000},"page":"109338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study)"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7201-8955","authenticated-orcid":false,"given":"Elin Marie","family":"Stensland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-2434","authenticated-orcid":false,"given":"Simone","family":"Stensgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1246-3048","authenticated-orcid":false,"given":"Inger Johanne Z.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3620-1555","authenticated-orcid":false,"given":"Yngvar","family":"Nilssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-6116","authenticated-orcid":false,"given":"Henrik","family":"Horndalsveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-8932","authenticated-orcid":false,"given":"Saulius","family":"Cicenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-1534","authenticated-orcid":false,"given":"Bj\u00f8rn Henning","family":"Gr\u00f8nberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-6226","authenticated-orcid":false,"given":"Simon","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin Holmskov","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boe Sandahl","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-8391","authenticated-orcid":false,"given":"Odd Terje","family":"Brustugun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109338_b0005","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1148\/radiol.2423051707","article-title":"Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases","volume":"242","author":"Mujoomdar","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.lungcan.2026.109338_b0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2016.03.009","article-title":"The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer","volume":"45","author":"Peters","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109338_b0015","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/apm.12328","article-title":"The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population","volume":"123","author":"Skov","year":"2015","journal-title":"APMIS"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109338_b0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31820db209","article-title":"EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery","volume":"6","author":"Helland","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109338_b0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109338_b0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109338_b0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109338_b0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109338_b0045","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109338_b0050","article-title":"Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC","author":"Janne","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109338_b0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11523-022-00941-7","article-title":"Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies","volume":"18","author":"Popat","year":"2023","journal-title":"Target. Oncol."},{"key":"10.1016\/j.lungcan.2026.109338_b0060","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251348429","article-title":"Therapeutic outcomes of osimertinib in EGFR \u2013 mutant non-small cell lung cancer with brain metastases: results from a retrospective study at Vietnam national cancer hospital","volume":"32","author":"Nguyen","year":"2025","journal-title":"Cancer Control"},{"key":"10.1016\/j.lungcan.2026.109338_b0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2022.08.004","article-title":"The evolving role of liquid biopsy in lung cancer","volume":"172","author":"Malapelle","year":"2022","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109338_b0070","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.23.01521","article-title":"Overall survival from the EORTC LCG-1613 APPLE trial of osimertinib versus gefitinib followed by osimertinib in advanced EGFR-mutant non-small-cell lung cancer","volume":"42","author":"Remon","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109338_b0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1): response assessment in solid tumours (RECIST): version 1.1 and supporting papers","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer (1990)"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109338_b0080","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"issue":"30","key":"10.1016\/j.lungcan.2026.109338_b0085","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1200\/JCO.23.02668","article-title":"Tyrosine kinase inhibitors with and without up-front stereotactic radiosurgery for brain metastases from EGFR and ALK oncogene-driven non-small cell lung cancer (TURBO-NSCLC)","volume":"42","author":"Pike","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2026.109338_b0090","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1158\/1078-0432.CCR-23-4035","article-title":"From rarity to reality: osimertinib's promising horizon in treating uncommon EGFR mutations in non\u2013small cell lung cancer","volume":"30","author":"Fukuda","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109338_b0095","doi-asserted-by":"crossref","first-page":"953","DOI":"10.21037\/tlcr-21-995","article-title":"Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials","volume":"11","author":"Eide","year":"2022","journal-title":"Transl Lung Cancer Res."},{"issue":"16","key":"10.1016\/j.lungcan.2026.109338_b0100","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/cncr.33571","article-title":"High concordance of actionable genomic alterations identified between circulating tumor DNA\u2013based and tissue\u2010based next\u2010generation sequencing testing in advanced non\u2013small cell lung cancer: the Korean Lung Liquid Versus Invasive Biopsy Program","volume":"127","author":"Park","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109338_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/ijc.ijc_438_21","article-title":"CONCORDANCE: a real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA versus tissue biopsy in patients with metastatic non-small cell lung cancer","volume":"59","author":"Prabhash","year":"2022","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109338_b0110","doi-asserted-by":"crossref","unstructured":"K.K. J\u00e4nne PA, J. Robichaux, C.K. Lee, S. Sugawara, T.Y. Yang, T.M. Kim, N. Yanagitani, S.W. Kim, A. Markovets, P. Bhetariya, L. Poole, D. Ghiorghiu, R. Hartmaier, J.C.H. Yang, D.V. Planchard. FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA Philadelphia (PA): AACR; Cancer Res. 84(7_Suppl) 2024:Abstract nr CT017. 2024.","DOI":"10.1158\/1538-7445.AM2024-CT017"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109338_b0115","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1200\/JCO.23.02219","article-title":"CNS efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer","volume":"42","author":"J\u00e4nne","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226000826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:55Z","timestamp":1790700355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226000826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"alternative-id":["S0169500226000826"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109338","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109338"}}